• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Synaptogenix Inc.

    6/23/25 4:05:13 PM ET
    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNPX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001571934
    NEUROTROPE BIOSCIENCE, INC.
    NEUROTROPE BIOSCIENCE INC.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Synaptogenix, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Synaptogenix, Inc.
    Street Address 1 Street Address 2
    1185 AVENUE OF THE AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    NEW YORK NEW YORK 10036 (973) 242-0005

    3. Related Persons

    Last Name First Name Middle Name
    WEINSTEIN ROBERT
    Street Address 1 Street Address 2
    1185 AVENUE OF THE AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode
    NEW YORK NEW YORK 10036
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    CHIEF FINANCIAL OFFICER
    Last Name First Name Middle Name
    SILVERMAN JOSHUA
    Street Address 1 Street Address 2
    1185 AVENUE OF AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode
    NEW YORK NEW YORK 10036
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    EXECUTIVE CHAIRMAN
    Last Name First Name Middle Name
    SINGER WILLIAM
    Street Address 1 Street Address 2
    1185 AVENUE OF AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode
    NEW YORK NEW YORK 10036
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    BERNSTEIN BRUCE T.
    Street Address 1 Street Address 2
    1185 AVENUE OF AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode
    NEW YORK NEW YORK 10036
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    SCHECHTER JONATHAN L.
    Street Address 1 Street Address 2
    1185 AVENUE OF AMERICAS 3RD FLOOR
    City State/Province/Country ZIP/PostalCode
    NEW YORK NEW YORK 10036
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-06-09    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    GP NURMENKARI INC. 000153480
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    22 ELIZABETH STREET
    City State/Province/Country ZIP/Postal Code
    NORWALK CONNECTICUT 06854
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    ILLINOIS
    NEW YORK
    OHIO

    13. Offering and Sales Amounts

    Total Offering Amount $5,500,000 USD
    or    Indefinite
    Total Amount Sold $5,500,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    5

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $385,000 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Synaptogenix, Inc. /S/ ROBERT WEINSTEIN ROBERT WEINSTEIN CHIEF FINANCIAL OFFICER 2025-06-23

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $SNPX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Singer William S. was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 700% to 10,566 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:07:09 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weinstein Robert was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 696% to 10,574 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:06:45 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Chairman Silverman Joshua was granted 41,919 shares and covered exercise/tax liability with 16,768 shares, increasing direct ownership by 1,644% to 26,681 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:06:21 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Synaptogenix Inc.

      PRE 14A - TAO Synergies Inc. (0001571934) (Filer)

      6/27/25 4:02:10 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TAO Synergies Inc. (0001571934) (Filer)

      6/27/25 4:00:50 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Synaptogenix, Inc. (0001571934) (Filer)

      6/24/25 4:37:19 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

      New name and stock symbol highlight strategic commitment to TAO, the leading AI cryptocurrency NEW YORK, July 1, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), formerly Synaptogenix, Inc. (NASDAQ:SNPX), announces that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TAOX," effective at the market open today, July 1, 2025. The new name and trading symbol coincides with the Company's previously announced digital asset treasury strategy focused exclusively on acquiring and staking TAO cryptocurrency. Executive Chairman Joshua Silverman commented, "With our team's deep knowledge of the TAO ecosystem and relationships in

      7/1/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

      New trading symbol "TAOX" effective Tuesday, July 1, 2025, New name represents Company's strategic focus on the synergies between cryptocurrency and AI NEW YORK, June 26, 2025 /PRNewswire/ -- TAO Synergies Inc. (the "Company"), formerly Synaptogenix, Inc. (NASDAQ:SNPX), today announced that it will begin trading on Nasdaq under the new ticker symbol "TAOX" on Tuesday, July 1, 2025, in accordance with its rebranding to the new name TAO Synergies Inc., effective today. The Company's new corporate identity aligns with its significant  strategic focus on the leading AI token TAO as the cornerstone of its digital asset treasury strategy. TAO is the leading AI token by market capitalization and

      6/26/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

      Strategic capital deployment into TAO advances Synaptogenix's blockchain treasury model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield NEW YORK, June 24, 2025 /PRNewswire/ -- Synaptogenix (NASDAQ:SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on artificial intelligence (Al) and machine learning. BitGo, the leading infrastructure provider of digital asset solutions, has been selected to provide qualified custody, staking and trading services for Synaptogenix's TAO holdings. BitGo brings unmatched expertise and a proven track record to help Synaptogen

      6/24/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

      Strategic capital deployment into TAO advances Synaptogenix's blockchain treasury model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield NEW YORK, June 24, 2025 /PRNewswire/ -- Synaptogenix (NASDAQ:SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on artificial intelligence (Al) and machine learning. BitGo, the leading infrastructure provider of digital asset solutions, has been selected to provide qualified custody, staking and trading services for Synaptogenix's TAO holdings. BitGo brings unmatched expertise and a proven track record to help Synaptogen

      6/24/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

      Singular focus on Bittensor (TAO), the leading AI token byadoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO equates to over two times the Company's current market capitalization; total acquisition target of $100 million NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altuch

      6/9/25 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

      Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Develo

      4/9/24 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Financials

    Live finance-specific insights

    See more
    • Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

      Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK, July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced changes to its Scientific Advisory Board (SAB) in preparation for Phase 2 data from its Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer's disease (AD).  The SAB is comprised of industry and academic leaders in science and drug development and will be instrumental in the further development of the Company's regenerative therapies across AD, Fragile X syndrome,

      7/26/22 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces Corporate Update Conference Call

      NEW YORK, July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take place on Tuesday, July 26th at 4:30pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. Drs. Tuchman and Alkon will also take live Q&A following their prepared remarks. The U.S. toll free dial-in for the conference call is (877) 407-8293, and the international dial-in number is 1-(201) 689-8349. Fo

      7/21/22 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

      NEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the Alzheimer's Association International Conference (AAIC) is now available entitled "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease (AD) Patients: A Regenerative Therapeutic Strategy." "Recent further analyses of pre-specified cohort results revealed clear evidence of Bryostatin therapeutic efficacy for advanced AD patients.  Analyses of treatment benefit, based on mean differences and as a function of successive dosing in

      7/26/21 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      2/6/24 10:16:19 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      2/8/23 6:05:21 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      1/18/23 4:28:57 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care